Cosmo pharmaceuticals

At Cosmo, we are committed to improve peoples lives by developing products that address unmet medical needs in the fields of gastroenterology, dermatology and healthtech.

Investors

Latest News

09 Jan 2025
AD HOC

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Read More
12 Dec 2024

Cosmo Pharmaceuticals appoints Chief Strategy Officer

Read More
18 Oct 2024

Cosmo shareholders approved Board proposal to appoint new independent auditor at today’s EGM

Read More

Upcoming Events

11 Mar 2025-13 Mar 2025

J.P. Morgan European Opportunities Forum

Add to Outlook
19 Mar 2025-20 Mar 2025

26th Kepler Cheuvreux Swiss Seminar

Add to Outlook
20 Mar 2025

Audited 2024 Full Year Results and Annual Report Publication

Add to Outlook

Latest presentation

09 Jan 2025
Corporate Update, Baader Swiss Equities 2025

Therapeutic Focus

Cosmo’s therapeutic focus is on the treatment of gastrointestinal diseases (including IBD, colonic infections and colorectal cancer – CRC), increase the effectiveness of endoscopic examinations and to treat persistent skin conditions, like acne, and androgenetic alopecia, that have a long-term physical and emotional impact on lives and self-esteem.

Find out more

Our Mission

To improve people’s lives by developing products that address unmet medical needs in the fields of gastroenterology, dermatology and healthtech.

Find out more

Manufacturing

We provide services related to the production of pharmaceutical products as: assessment of manufacturing processes, technology transfer, evaluation of pharmaceutical product stability, testing and release to the market and drafting of the necessary documentation for pharmaceutical products’ registration.

Find out more